EMC Helps Leading Vaccine Manufacturer Boost IT Efficiency; Reduces TCO 20% With Life Sciences Solution

HOPKINTON, Mass., Jan. 8, 2013 /PRNewswire/ -- EMC Corporation (NYSE: EMC) today announced that Sanofi Pasteur, a world leading vaccine manufacturer producing more than 1 billion doses of vaccine per year, has deployed EMC® Documentum® D2, enabling the company to accelerate time-to-value through the power of configuration. Documentum D2 is a content management application with a modern, configurable and intuitive user experience for the EMC® Documentum® platform, and a key component of the Documentum for Life Sciences solution. This solution has enabled Sanofi Pasteur to transform business, and modernize its content management system into a unified, document control and compliance infrastructure for managing mission-critical regulated content. 

Customer Benefits of the EMC Documentum Life Sciences Solution:

• Simplified IT management —Flexible lifecycles, workflow automation, and advanced configuration and usability enables Sanofi Pasteur's IT staff to focus on innovation and business-critical projects instead of addressing technical issues – providing Sanofi's IT team a 4x boost in productivity. 
• Cost Savings — Leveraging pure application configuration vs. internal development enabled Sanofi Pasteur to eliminate need for custom coding and reduce validation costs resulting in a 20% TCO savings.
• Improved process quality and collaboration — Unified architecture built on DIA EDM reference model, ensures process consistency, enables collaborative authoring, and seamless document control across internal and external boundaries including R&D, quality and manufacturing, clinical development, and contract/clinical research organizations (CROs).
• Reliable Compliance — Automated enforcement of policies, reporting, e-signature support, and full audit trails enable compliance with global regulations and industry standards such as FDA 21 CFR Part 11, GxP, and TMF reference models.

Sanofi Pasteur offers a broad range of vaccines protecting against 20 infectious diseases across 12 globally dispersed production sites, requiring compliance with local and international quality and regulatory procedures.

1 2 3 Next › Last »